Gestational sac

Third Pole Therapeutics Announces Successful Completion of Feasibility Study with eNOfit™ Portable Inhaled Nitric Oxide Delivery System

Retrieved on: 
Tuesday, February 27, 2024

This study evaluated eNOfit™, a miniaturized, portable inhaled nitric oxide (iNO) generator and delivery system for the ambulatory treatment of patients suffering from pulmonary hypertension (PH) associated with Interstitial Lung Disease (ILD).

Key Points: 
  • This study evaluated eNOfit™, a miniaturized, portable inhaled nitric oxide (iNO) generator and delivery system for the ambulatory treatment of patients suffering from pulmonary hypertension (PH) associated with Interstitial Lung Disease (ILD).
  • “The successful completion of our EFS which validated the safe and practical use of our eNOfit™ system, enables us to confidently move into larger randomized placebo-controlled safety and efficacy studies.
  • Importantly, this value creating milestone will trigger the final funding of Third Pole’s Series B investment round.” said Bill Athenson, CEO of Third Pole.
  • Inhaled nitric oxide relaxes smooth muscle within the pulmonary vasculature, increasing the diameter of pulmonary arteries and decreasing their resistance to blood flow.

Why do people and animals need to breathe? A biologist explains why you need a constant source of oxygen

Retrieved on: 
Tuesday, February 6, 2024

But to turn it into energy, they need one more ingredient – oxygen.

Key Points: 
  • But to turn it into energy, they need one more ingredient – oxygen.
  • All living things need oxygen, except for some bacteria and a few tiny animals that don’t.
  • Because you need a lot of oxygen, your lungs need a lot of surface area to do their job.
  • That means you need to take five breaths just to get the equivalent of one complete lungful of oxygen.

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Daxas, roflumilast, Date of authorisation: 05/07/2010, Revision: 20, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Daxas, roflumilast, Date of authorisation: 05/07/2010, Revision: 20, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Daxas, roflumilast, Date of authorisation: 05/07/2010, Revision: 20, Status: Authorised

GPCR Therapeutics Announces Out-Licensing Agreement with Bridge Biotherapeutics in Idiopathic Pulmonary Fibrosis

Retrieved on: 
Thursday, December 14, 2023

SEOUL, Korea and REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage international biopharmaceutical company, announces it enters into an out-licensing agreement with Bridge Biotherapeutics (KQ288330) for the CXCR4-LPA1 inhibitor combination method of treatment.

Key Points: 
  • SEOUL, Korea and REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage international biopharmaceutical company, announces it enters into an out-licensing agreement with Bridge Biotherapeutics (KQ288330) for the CXCR4-LPA1 inhibitor combination method of treatment.
  • In collaboration with Bridge Biotherapeutics, GPCR will pursue joint development and commercialization of the combination therapy.
  • Conducting a multinational phase 2a clinical trial of BBT-877, an autotaxin inhibitor for the treatment of IPF, Bridge Biotherapeutics has been accelerating development of its proprietary IPF pipeline.
  • The target GPCRs are known to promote fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).

Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally

Retrieved on: 
Thursday, December 7, 2023

According to the World Health Organization , COPD is the third deadliest disease in the world.

Key Points: 
  • According to the World Health Organization , COPD is the third deadliest disease in the world.
  • Today, there are an estimated 480 million people who suffer from COPD.
  • This study in JAMA Network Open projects the increased regional and global burden of COPD by 2050 through an analysis of historical COPD prevalence and data on COPD risk factors such as tobacco smoking, outdoor air pollution, and household air pollution.
  • “The disproportionate growth of COPD among women is a critical finding as COPD has not always been as prevalent in women.

Marijuana, Cigarette Smokers at Increased Risk of Emphysema

Retrieved on: 
Tuesday, November 28, 2023

To determine the effects of marijuana and cigarette smoking, researchers for the multicenter prospective study examined the chest CT images of four patient groups: non-smokers, cigarette smokers, marijuana smokers, and combined marijuana and cigarette smokers.

Key Points: 
  • To determine the effects of marijuana and cigarette smoking, researchers for the multicenter prospective study examined the chest CT images of four patient groups: non-smokers, cigarette smokers, marijuana smokers, and combined marijuana and cigarette smokers.
  • Marijuana smokers included in the study had smoked marijuana at least four times a month for two years.
  • Centrilobular emphysema is a type of pulmonary emphysema where the air sacs within the lungs are damaged.
  • "The mean number of marijuana smoking years was less than compared to cigarette smokers and combined marijuana and cigarette smokers," Dr. Kang said.

GPCR Therapeutics Expands Pipeline into Fibrosis with a Combination Approach Targeting LPA1

Retrieved on: 
Tuesday, October 10, 2023

(1) (2)

Key Points: 
  • (1) (2)
    LPA1 and CXCR4 are among the few targets for which IPF therapeutics are being clinically developed respectively.
  • The company’s lead pipeline targets CXCR4 and B2AR (beta-2 adrenergic receptor) in cancer and is currently undergoing a phase 2 clinical trial.
  • Based in part on the research announced today, the company has expanded its portfolio and begun developing a pipeline targeting CXCR4 and LPA1 in fibrosis.
  • It is another example of the potential of our CXCR4-GPCR pairs approach, where several novel valuable mechanisms can be discovered.

RS BioTherapeutics and National Institutes of Health Execute Research Collaboration Agreement to Evaluate Prevention and Treatment of Idiopathic Pulmonary Fibrosis

Retrieved on: 
Tuesday, August 29, 2023

According to NIH , idiopathic pulmonary fibrosis (IPF) is a serious, chronic disease that affects the tissue surrounding the air sacs, or alveoli, in the lungs.

Key Points: 
  • According to NIH , idiopathic pulmonary fibrosis (IPF) is a serious, chronic disease that affects the tissue surrounding the air sacs, or alveoli, in the lungs.
  • This condition develops when lung tissue becomes thick and stiff for unknown reasons.
  • Over time, these changes can cause permanent scarring in the lungs, called fibrosis, that makes it progressively more difficult to breathe.
  • Commentating on the Research Collaboration Agreement with NIH, Michelle L. Shuffett, MD, Chief Medical Officer of RS BioTherapeutics said, “We are incredibly pleased to be working in a collaborative manner with NIH to evaluate our cornerstone compound, RSBT-001, in an animal pulmonary fibrosis model.